Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

811 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial).
Baldin P, Carrasco J, Beniuga G, Jouret-Mourin A, Demolin G, Roland S, D'Hondt L, Vergauwe P, Van Daele D, Mailleux M, Sinapi I, De Cuyper A, Blétard N, Massart B, Delos M, Castella ML, van Maanen A, Van den Eynde M. Baldin P, et al. Among authors: carrasco j. Cancers (Basel). 2022 Feb 24;14(5):1183. doi: 10.3390/cancers14051183. Cancers (Basel). 2022. PMID: 35267491 Free PMC article.
Prognostic assessment of resected colorectal liver metastases integrating pathological features, RAS mutation and Immunoscore.
Baldin P, Van den Eynde M, Mlecnik B, Bindea G, Beniuga G, Carrasco J, Haicheur N, Marliot F, Lafontaine L, Fredriksen T, Lanthier N, Hubert C, Navez B, Huyghe N, Pagès F, Jouret-Mourin A, Galon J, Komuta M. Baldin P, et al. Among authors: carrasco j. J Pathol Clin Res. 2021 Jan;7(1):27-41. doi: 10.1002/cjp2.178. Epub 2020 Sep 9. J Pathol Clin Res. 2021. PMID: 32902189 Free PMC article.
Pathological responses after angiogenesis or EGFR inhibitors in metastatic colorectal cancer depend on the chemotherapy backbone.
Carrasco J, Gizzi M, Pairet G, Lannoy V, Lefesvre P, Gigot JF, Hubert C, Jouret-Mourin A, Humblet Y, Canon JL, Sempoux C, Chapaux X, Danse E, Tinton N, Navez B, Van den Eynde M. Carrasco J, et al. Br J Cancer. 2015 Nov 3;113(9):1298-304. doi: 10.1038/bjc.2015.321. Epub 2015 Oct 13. Br J Cancer. 2015. PMID: 26461062 Free PMC article.
Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.
Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, Sclafani F. Vandeputte C, et al. Among authors: carrasco j. Clin Colorectal Cancer. 2021 Dec;20(4):326-333. doi: 10.1016/j.clcc.2021.07.006. Epub 2021 Jul 24. Clin Colorectal Cancer. 2021. PMID: 34404621 Clinical Trial.
Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer.
Bregni G, Vandeputte C, Pretta A, Senti C, Trevisi E, Acedo Reina E, Kehagias P, Liberale G, Moretti L, Bali MA, Demetter P, Flamen P, Carrasco J, D'Hondt L, Geboes K, Gokburun Y, Peeters M, Van den Eynde M, Van Laethem JL, Vergauwe P, Chapot CA, Buyse M, Deleporte A, Hendlisz A, Sclafani F. Bregni G, et al. Among authors: carrasco j. Acta Oncol. 2021 Apr;60(4):549-553. doi: 10.1080/0284186X.2020.1871067. Epub 2021 Jan 13. Acta Oncol. 2021. PMID: 33435735 Clinical Trial. No abstract available.
Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival.
Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, Lafontaine L, Haicheur N, Marliot F, Debetancourt D, Pairet G, Jouret-Mourin A, Gigot JF, Hubert C, Danse E, Dragean C, Carrasco J, Humblet Y, Valge-Archer V, Berger A, Pagès F, Machiels JP, Galon J. Mlecnik B, et al. Among authors: carrasco j. J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx123. J Natl Cancer Inst. 2018. PMID: 28922789
Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor.
Vandeputte C, Kehagias P, El Housni H, Ameye L, Laes JF, Desmedt C, Sotiriou C, Deleporte A, Puleo F, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Marechal R, Galdon MG, Heimann P, Paesmans M, Flamen P, Hendlisz A. Vandeputte C, et al. Among authors: carrasco j. Oncotarget. 2018 Apr 3;9(25):17756-17769. doi: 10.18632/oncotarget.24879. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707145 Free PMC article.
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer.
Mardjuadi FI, Carrasco J, Coche JC, Sempoux C, Jouret-Mourin A, Scalliet P, Goeminne JC, Daisne JF, Delaunoit T, Vuylsteke P, Humblet Y, Meert N, van den Eynde M, Moxhon A, Haustermans K, Canon JL, Machiels JP. Mardjuadi FI, et al. Among authors: carrasco j. Target Oncol. 2015 Sep;10(3):375-83. doi: 10.1007/s11523-014-0342-9. Epub 2014 Oct 11. Target Oncol. 2015. PMID: 25304881 Clinical Trial.
Celyad's novel CAR T-cell therapy for solid malignancies.
Lonez C, Hendlisz A, Shaza L, Aftimos P, Vouche M, Donckier V, Machiels JH, Van Den Eynde M, Canon JL, Carrasco J, Odunsi K, Sahebjam S, Rottey S, Braun N, Verma B, Gilham DE, Lehmann FF. Lonez C, et al. Among authors: carrasco j. Curr Res Transl Med. 2018 May;66(2):53-56. doi: 10.1016/j.retram.2018.03.001. Epub 2018 Apr 4. Curr Res Transl Med. 2018. PMID: 29625833 Review.
811 results